Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck

Equality Impact Assessment (Guidance development) (PDF 231 KB)

Final appraisal determination

Final appraisal determination document (PDF 412 KB)

Committee papers (PDF 1.06 MB)

Public committee slides (PDF 895 KB)

Draft guidance: 1

Appraisal consultation document (PDF 286 KB)

Committee papers (PDF 2.47 MB)

Final scope (PDF 33 KB)

Final matrix (PDF 98 KB)

Consultation document RPP Proposal paper (PDF 226 KB)

Provisional matrix (post-referral) RPP Matrix (PDF 60 KB)

Final appraisal determination document (PDF 113 KB)

Committee papers Response to C&C comments on ACD (PDF 130 KB)

Committee papers C&C ACD comments (PDF 270 KB)

Committee papers Expert ACD comments (PDF 15 KB)

Committee papers ERG comments on additional evidence (PDF 55 KB)

Committee papers EMEA assessment report (PDF 431 KB)

Consultation document (PDF 104 KB)

Committee papers Company submissions (PDF 1.24 MB)

Committee papers C&C submissions (PDF 184 KB)

Committee papers Expert statements (PDF 332 KB)

Committee papers ERG Report (PDF 608 KB)

Committee papers PMB (PDF 167 KB)

Final scope (PDF 29 KB)

Final matrix (PDF 59 KB)

NICE's response to comments on the draft scope and provisional matrix Comments on draft scope (PDF 69 KB)

NICE's response to comments on the draft scope and provisional matrix Comments on provisional matrix (PDF 33 KB)